Clinical trials: Stem Cell Mobilization
Diamond Blackfan Anemia
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia
This study will provide information needed to develop more effective treatments for patients with Diamond-Blackfan anemia (DBA). Current treatments include steroids, such as prednisone, and blood transfusions.
- Trial name
- NCT00011505
- Testing
- G-CSF, Leukapheresis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Cancer
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells.
- Trial name
- NCT00003553
- Testing
- HLA Matched Peripheral BLood Stem Cells
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Granulomatous Disease X-linked (X-CGD)
Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
- Trial name
- XCGD-MOBI (NCT03055247)
- Testing
- Ibuprofen, Myelostim, Mozobil
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
LAD-1, DOCK8
Apheresis of Patients With Immunodeficiency
Background: Gene therapy is being investigated as a possible treatment for individuals with immunodeficiency diseases or other conditions that make it difficult to fight off infection.
- Conditions
- LAD-1, DOCK8, GATA2 Deficancy
- Trial name
- NCT01212055
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Myeloma and Malignant Lymphoma
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.
- Trial name
- NCT05007652
- Testing
- KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor)
- Where
- 21 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT02639559
- Testing
- BL-8040, Leukapheresis, Hematopoietic cell transplant
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°)
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL)
- Trial name
- R²-DHAP (NCT02983097)
- Testing
- Rituximab, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Lymphoma, Multiple Myeloma
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.
The purpose of this study is to determine the safety of parathyroid hormone in combination with G-CSF when used as a stem cell mobilization regimen for patients who fail to mobilize sufficient progenitor stem cells after one or…
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia
- Trial name
- NCT00299780
- Testing
- Stem cell mobilization
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Non-Hodgkin Lymphoma
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT01018979
- Testing
- TG-0054 (2.24 mg/kg), TG-0054 (3.14 mg/kg)
- Where
- 6 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- GPCR Therapeutics, Inc.
Germ Cell Tumor, Teratoma
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned…
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma
- Trial name
- NCT02375204
- Testing
- paclitaxel, ifosfamide, cisplatin
- Where
- 125 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Normal PBPC Donors
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.
- Trial name
- NCT00115128
- Testing
- filgrastim
- Volunteers
- 309 people
- Sponsor
- Amgen
Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)…
- Trial name
- NCT06520163
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 17 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Acute Myeloid Leukemia (AML)
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body…
- Trial name
- NCT00363467
- Testing
- G-CSF, Leukapheresis, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myocardial Infarction
Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement
One emerging concept is that some form of injury or inflammation is a prerequisite for the success of circulating-cell participation in differentiated tissue structure and function.
- Trial name
- NCT00154466
- Testing
- cardiac rehabilitation
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Taiwan University Hospital
Hypertrophic Obstructive Cardiomyopathy
Mobilization of Endothelial Progenitor Cells and Aspirin
Aspirin at doses used during acute myocardial infarction may inhibit the mobilization of endothelial progenitor cells (EPCs).
- Trial name
- TROPHIC 3 (NCT02674958)
- Testing
- Aspirin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
PEPCAD III Substudy: Stem Cell Mobilization
The aim of the PEPCAD III substudy is to assess the efficacy of the Paclitaxel-eluting DEBlue stent system in the treatment of stenoses in native coronary arteries compared to the Sirolimus-eluting Cypher stent by intravascular…
- Trial name
- PEPCADIIIsub (NCT00473499)
- Testing
- DEBlue vs Cypher vs BMS
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital, Saarland
Granulocyte Colony-stimulating Factor, Stem Cell Mobilization
A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF
Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic…
- Trial name
- NCT05409547
- Testing
- PEG-rhG-CSF
- Volunteers
- 80 people
- Sponsor
- Ning Huang
Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received…
- Conditions
- Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line Mobilization, Transplantation
- Trial name
- PREDICT (NCT00838357)
- Testing
- Generic = Plerixafor
- Where
- 26 sites in France, Germany and 5 more
- Volunteers
- 118 people
- Sponsor
- Genzyme, a Sanofi Company